Firvanq™ (vancomycin) – New drug approval
January 29, 2018 - CutisPharma announced the FDA approval of Firvanq (vancomycin) powder for oral solution, in adults and pediatric patients less than 18 years of age for the treatment of Clostridium difficile-associated diarrhea (CDAD) and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
Top